Voluntary #LicensingSavesLives by making medicines and health technologies affordable for low- and middle-income countries. 🌍 🤝 But we cannot achieve this great change without your help! 👉 medicinespatentpool.org/licensingsav...

Last week, our India and Geneva teams came together for the annual all-staff retreat, a great moment to reflect and plan ahead.☀️ We explored MPP’s future strategy, priorities and ongoing #LicensingSavesLives campaign. Thank you to all colleagues for your energy, we look forward to what lies ahead!

Around 375 patients with #chronicmyeloidleukaemia (CML) in El Salvador, Indonesia & the Philippines are now accessing quality-assured generic #nilotinib. Made possible through a #voluntarylicence from @novartis.bsky.social to MPP via the ATOM coalition - @uiccofficial.bsky.social! lnkd.in/eruiP-Gv

🌍 MPP joined the Joint @who.int @unaids.org @unitaid.bsky.social annual consultation! Judith Federhofer shared updates on long-acting HIV treatment and the CAB-LA licence amendment for treatment + PrEP. @eburrone.bsky.social discussed access and pricing for #long-acting prevention in LMICs.

We’re proud to be recognized in the 2025 Global Health 50/50 Report as a high performer! MPP’s new Menstrual & Menopause Policy supports women’s health needs through flexible work, awareness & training. Read more: global5050.org/2025-report/

MPP welcomes the updated @who.int Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc). We remain committed to enabling #access to essential medicines through #voluntarylicensing, #technologytransfer, and #manufacturing support. 👉 lnkd.in/dmr98RHf

📢 MPP is looking for a new Expert Advisory Group (EAG) Member! 🗓️ Deadline to apply: 31 August 2025 📩 Apply by sending your CV and cover letter to [email protected] More info 👉 medicinespatentpool.org/who-we-are/c... #Vaccines #AccessToMedicines #PublicHealth #JobOpportunities

🌍 Join our mission 📢 Request for Proposals – Feasibility and Concept Design Expert – GMP mRNA Vaccine Manufacturing in Africa
 📢 Request for Proposals – GLP1-RA Market Assessment for Obesity Treatment.
 📢 Board Member Opportunity 👉 medicinespatentpool.org/who-we-are/c...

Taking HIV pills daily can be overwhelming. 💉 Long-acting injectables offer hope, safe and effective. LMICs still lack timely access. #Voluntarylicensing can change that, ensuring the most vulnerable benefit from innovation. 📖 www.sciencedirect.com/science/arti... 👉 www.youtube.com/watch?v=GGDM...

📢 Request for Proposal – GLP1-RA Market Assessment for Obesity Treatment 🗓 Deadline for submission: 7 September 2025 👉 To apply, send your proposal to [email protected] Full details here: medicinespatentpool.org/who-we-are/c...

🌟 Welcoming our new Expert Advisory Group members! We are delighted to welcome four new members to the @medicinespatentpool.org’s EAG. 🙏 A thank you to all our EAG members for their continued support and expertise in advancing MPP’s mission to increase #access to life-saving medicines 🌏.

🚨 We’re hiring! ⚖️ Associate Counsel 💉 Consultant: Feasibility & Concept Design Expert 👉 Check out our career page for more information: medicinespatentpool.org/who-we-are/c... #GlobalHealth #AccessToMedicines #mRNA #Vaccines #Hiring

🌍 #WorldHepatitisDay2025 Charles Gore, founder of World Hepatitis Day, @worldhepalliance.bsky.social and MPP’s Executive Director, reminds us: 1.3M people die each year from viral hepatitis, and these deaths are preventable. 🔗 Full message: medicinespatentpool.org/news-publica...

🚨 We’re hiring! ⚖️ Associate Counsel 💉 Consultant: Feasibility & Concept Design Expert 👉 Check out our career page for more information: medicinespatentpool.org/who-we-are/c... #GlobalHealth #AccessToMedicines #mRNA #Vaccines #Hiring

“We don’t have to explain ourselves all over again.” In Kigali, we visited HDI, led by Dr. Aflodis Kagaba, where sex workers, LGBTQ+ people & people who use drugs find stigma-free care, every day. ✍️ Read the full story: medicinespatentpool.org/story-post/b...

Mila Maistat, Senior Manager at MPP, took part in the ASEAN dialogue on access to ARVs 🌏 🤝 She joined discussions with governments, health professionals, and communities to review progress in ARV access through MPP licences and the transition to WHO-recommended first-line treatments.

🔬 MPP's prioritisation framework guides our focus towards interventions where voluntary licensing can have the greatest public health impact. 📘 Our 2024 annual report: medicinespatentpool.org/news-publica... 👉 Our prioritisation page: medicinespatentpool.org/progress-ach...

Too many children are given medicines that were never properly tested for them. That means imprecise dosing—and real risks. 💡 The Global Accelerator for Paediatric Formulations Network (GAP-f) is changing the game. 🔗 bit.ly/4lkpLZk

Unitaid applauds ViiV Healthcare and the @medicinespatentpool.org for advancing equitable access to HIV treatment. Strong partnerships like this help deliver life-changing innovations to the communities that need them most. Learn more: medicinespatentpool.org/news-publica...

Many essential medicines are not designed for children. That means crushed pills, inaccurate doses, and bitter tastes that make treatment hard to take. The Global Accelerator for Paediatric Formulations Network (GAP-f) is working to close this gap. 🔗 bit.ly/4lkpLZk #HealthForAll

Expanding the #voluntarylicence for cabotegravir long-acting from #HIV prevention to treatment builds on 10+ years of #MPP–#ViiVHealthcare collaboration. Founded by #Unitaid in 2010, MPP helped 23M+ access DTG—now doing the same for CAB LA with generic partners for prevention and treatment.

The MPP and ViiV have expanded their agreement to now include cabotegravir long-acting for both #HIV prevention and treatment. This is the first fully long-acting HIV treatment made available through a voluntary licence in low- and middle- income countries. #IAS2025 #ViiV #Unitaid

"Expanding our licence with ViiV Healthcare to include long-acting cabotegravir for #HIV treatment marks a significant step forward for equitable access” - @medicinespatentpool.org's Esteban Burrone 🇨🇭 #IAS2025

💡 Have you explored the latest features of #LAPaL? Our long-acting therapeutics database just got even better — designed to support the public health community with richer tools and insights. 🧪🌍 🔗 Dive in: lapal.medicinespatentpool.org#/?filters=%7...

👏 MPP extends its sincere thanks to the China Chamber of Commerce for Import and Export of Medicines and Health Products (#CCCMHPIE) for a successful seminar during #CPHI&PMECChina! 🇨🇳 We look forward to building on this dialogue to expand access to essential #medicines.

Our MPP team will be attending @iasociety.bsky.social 2025 in Kigali next week! 🇷🇼 Reach out to explore new collaboration opportunities to advance #globalhealth together 🌍 Judith Federhofer - @eburrone.bsky.social - Gelise McCullough - ‪@sebmoringva.bsky.social - Manuele Piccolis #IAS2025

Looking forward to reconnecting at #IAS2025 and achieving #health #impact! @medicinespatentpool.org @iasociety.bsky.social

🚨 Don’t miss the next #BetterMeds4Kids webinar on 8 July! It will spotlight the latest on Respiratory Syncytial Virus (RSV), featuring insights from the April PAediatric Drug Optimization (PADO) meeting, which brought together top global health experts. 🎟️ Register now: who.zoom.us/webinar/regi...

💡Did you know that 70,000 deaths each year are caused by postpartum haemorrhage – 90% occurring in low- and lower-middle income countries? That's why MPP signed an agreement for a conditional licence for heat-stable carbetocin with Ferring Pharmaceuticals. 👉 medicinespatentpool.org/news-publica...

Did you know that since the MPP & ViiV Healthcare agreement of 2014, 24 million people in 129 LMICs have benefited from state-of-the-art generic HIV treatment? 90% of those on antiretroviral treatment were on DTG-based regimens, over 1Bn packs of DTG delivred. medicinespatentpool.org/news-publica...

📘 MPP's 2024 annual report, Breaking New Ground, shows that we continued to bring positive change for millions of people in LMICs across the globe, 🌍 with a significant expansion in #treatment uptake, #economic savings and #health benefits. 👉 medicinespatentpool.org/news-publica...

Key takeaways from this week's G20 Health WG Side Event in Johannesburg: 🧬 Equity must be intentional 🏭 R&D drives local production 🔁 Full tech transfer = real sovereignty 💰 Finance + political will = lasting impact #G20Health #PandemicPreparedness

🎥 Dr. Giulia Segafredo, Senior NCDs Access Manager at the @medicinespatentpool.org, Geneva, and Dr. Dario Trapani, Medical Oncologist at the European Institute of Oncology, Milan, discuss their #ASCO2025 research with @ecancer.org. 👉 ecancer.org/en/video/123...

🎤 At #ASCO2025, Giulia Segafredo shared a cost-effectiveness analysis of immune checkpoint inhibitors for lung cancer in 🇮🇳 India & 🇿🇦 South Africa. 🫁 Lung cancer is the top cancer killer worldwide. ICIs work but are often too costly in LMICs. 📄 Details: meetings.asco.org/abstracts-pr...

We’re thrilled to announce that the dedicated mRNA Technology Transfer Programme page on LinkedIn is live, the global initiative focused on improving health equity by building sustainable mRNA vaccine manufacturing capabilities in LMICs! 🔗 Follow the page: lnkd.in/dpKuv5b5 👉 www.mrnaProgramme.org

🌍 How can we ensure life-saving medicines reach all who need them, benefiting patients, originators, and generics alike? 💬 In this episode of @wipo.int’s Mission Imagination, Charles Gore shares how MPP’s #voluntarylicensing model is driving global health impact. 🎥 www.youtube.com/watch?v=im9q...

🧭 MPP’s Board & observers met in Geneva this week. Grateful for their expertise and guidance 🙏 — and proud of our team’s professionalism and commitment to impact 💼🌍 #GlobalHealth #MPP #AccessToMedicines

📢 Charles Gore, MPP Executive Director: 🗣️ “How can we hear and amplify the voices of children globally in our collective push for better access to adapted medicines?” 🤝 MPP is looking forward to continuing the collaboration with GAP-f partners to drive impactful actions toward #BetterMeds4Kids 👶

📢 At the 1st Intl Workshop on Long-Acting Anti-Infectives, Lobna Gaayeb spotlighted LAPaL—a free resource on long-acting tech & formulations. 💡 lapal.medicinespatentpool.org#/ @unitaid.bsky.social @liverpooluni.bsky.social @celtliverpool.bsky.social #LEAP @academicmededu.bsky.social

At #WHA78, MPP reaffirmed its commitment to equity in global health: 💊 Access to affordable NCD meds in LMICs 🤝 Support for WHO Pandemic Agreement on licensing & local production 🍼 Access to RSV monoclonal antibodies for preterm infants 👉 Full statements: medicinespatentpool.org/news-publica...

🎙️ “The mRNA Technology Transfer Programme is still in its early days, but it holds huge promise, if we support it together.” A key takeaway from our #WHA78 side event, co-hosted with the Permanent Representative of France and @medicinespatentpool.org 🔗 lnkd.in/eUtQsNMv @who.int

🌍 🤝 We just signed an MOU with #Vizuri Health Dynamics and @medicinespatentpool.org! This partnership will focus on understanding the African pharmaceutical sector, leveraging networks, and fostering product adoption. Exciting times ahead. #AccessToMedicines #LocalProduction #HealthInnovation

🌍 Join us at #WHA78 for a week of global health events! 📅 19 May 🔗 medicinespatentpool.org/news-publica... 📅 20 May 🔗 medicinespatentpool.org/news-publica... 📅 21 May | 08:15–10:00 CET 🔗 www.worldhepatitisalliance.org/news/wha78/ 📅 21 May | 18:00–19:20 CET 🔗 docs.google.com/forms/d/e/1F...

📰 The #MPP May 2025 Newsletter is out! 📢 Highlights include: - The first sublicense under WHO’s Health Tech Access Programme - A preview of MPP’s pre-events at hashtag#WHA78 - Release of our 2024 Prioritisation Report 👉 Read more: lnkd.in/ezTGcS5Z 📝 Didn’t receive our newsletter? lnkd.in/dJA7kkue

A week and a half to go until we can #share more on our GAP-f #work on #BetterMeds4Kids for the coming 5 years of our next #strategic phase! Join us! #GlobalHealth @who.int / @dndi.org / @egpaf.bsky.social / @iasociety.bsky.social / @gardp.bsky.social / @mmv.org / @medicinespatentpool.org / Temasek

Unitaid funded the studies required for @who.int prequalification, working under a @medicinespatentpool.org license. This support ensured that TLD met global quality standards and could be supplied through international procurement channels. 🧵👇

Unitaid a financé les études nécessaires à la préqualification par @who.int du TLD, dans le cadre d’une licence du @medicinespatentpool.org. Ce soutien a permis d’aligner le produit sur les normes mondiales et d’ouvrir la voie à son approvisionnement international.

Big news for #diagnostic equity in Africa! WHO & MPP have signed the first #HTAP sublicense with 🇳🇬 Nigeria’s Codix Bio to produce rapid diagnostic tests using #tech from SD Biosensor 🇰🇷. 👉 medicinespatentpool.org/news-publica... @who.int #CodixBio

The 2025 MPP Prioritisation Report is out — spotlighting key medicines and health technologies for expanded global access! 🌍 🔗 Read the full report: medicinespatentpool.org/progress-ach... @unitaid.bsky.social @accesstomedicinefoundation.org @jayiyer.bsky.social

Curious about our #GlobalHealth #Access and #Equity work? 🤷 Check out these key publications by medicinespatentpool.org and partners! 😎 lnkd.in/eumekg9R